Evommune (EVMN) Capital Expenditures (2025 - 2026)

Evommune's (EVMN) quarterly Capital Expenditures came in at $38000.0 in Q1 2026, up 139.58% on a QoQ basis from -$96000.0 in Q4 2025.

Evommune (EVMN) Capital Expenditures (2025 - 2026) Analysis & Trends

Evommune (EVMN) has 2 years of Capital Expenditures data on file, last reported at $38000.0 in Q1 2026.

On a quarterly basis, Capital Expenditures changed N/A year-over-year to $38000.0 in Q1 2026; TTM through Mar 2026 was -$58000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $35000.0, down 60.23% from the prior year.
Capital Expenditures for Q1 2026 stood at $38000.0, up from -$96000.0 in the prior quarter.
Over the last five years, Capital Expenditures for EVMN reached as high as $38000.0 in Q1 2026 and fell as low as -$96000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	Evommune	381.48 Mn	170.02 Mn	-	38,000.00

Download Data